
Scientists from Bristol-Myers Squibb Company have developed a novel approach for the simultaneous quantitation of neutralizing antibodies, residual drug, and human Immunoglobulin G (IgG) in immunogenicity assay development using liquid chromatography?tandem mass spectrometry (LC–MS–MS). This work published in Analytical Chemistry presents a new approach that aids the refinement of therapeutic protein neutralizing antibody assays in drug development.










